TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Anti-CD30 drugs, such as brentuximab vedotin, have been evaluated in treating advanced stages of CTCL with a significant clinical response observed (NCT01396070, NCT01578499) (114, 116, 117).